Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C; Seattle Cancer Care Alliance Network Investigators; Specht J. Symonds L, et al. Among authors: jenkins i. Clin Breast Cancer. 2019 Apr;19(2):e283-e296. doi: 10.1016/j.clbc.2018.12.008. Epub 2018 Dec 14. Clin Breast Cancer. 2019. PMID: 30737173 Free PMC article. Clinical Trial.
Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.
Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM. Peterson LM, et al. Among authors: jenkins i. J Nucl Med. 2018 Dec;59(12):1823-1830. doi: 10.2967/jnumed.118.211102. Epub 2018 May 10. J Nucl Med. 2018. PMID: 29748233 Free PMC article.
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.
Symonds L, Jenkins I, Linden HM, Kurland B, Gralow JR, Gadi VVK, Ellis GK, Wu Q, Rodler E, Chalasani P, Chai X, Riedel J, Scca Network Investigators, Stopeck A, Brown-Glaberman U, Specht JM. Symonds L, et al. Among authors: jenkins i. Clin Breast Cancer. 2022 Jan;22(1):32-42. doi: 10.1016/j.clbc.2021.05.009. Epub 2021 May 24. Clin Breast Cancer. 2022. PMID: 34158245 Free PMC article. Clinical Trial.
266 results